Effects of the antioxidant baicalein on the pharmacokinetics of nimodipine in rats: A possible role of P-glycoprotein and CYP3A4 inhibition by baicalein

Pharmacological Reports

Volumn 63, Issue 4, 2011, Pages 1066-1073

  Cho, Young Ah ^a   Choi, Jun Shik ^b   Burm, Jin Pil ^c  

^a Gyeongsang National University School of Medicine   (South Korea)

^b Chosun University   (South Korea)

^c Chosun Nursing College   (South Korea)

Author keywords

Baicalein; Bioavailability; CYP3A4; Nimodipine; P glycoprotein; Pharmacokinetics

Indexed keywords

BAICALEIN; CYTOCHROME P450 3A4; GLYCOPROTEIN P; NIMODIPINE; RHODAMINE 123;

ANIMAL EXPERIMENT; ANTIOXIDANT ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CELL STRAIN MCF 7; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG POTENTIATION; ENZYME INHIBITION; HUMAN; HUMAN CELL; LIVER METABOLISM; MALE; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; NONHUMAN; PROTEIN EXPRESSION; PROTEIN SYNTHESIS INHIBITION; RAT; SINGLE DRUG DOSE; SMALL INTESTINE; TIME TO MAXIMUM PLASMA CONCENTRATION;

EID: 80053366326     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: 10.1016/S1734-1140(11)70624-7     Document Type: Article

References (35)

1. Chieli E, Romiti N, Cervelli F, Tongiani R: Effects of flavonols on P-glycoprotein activity in cultured rat hepatocytes. Life Sci, 1995, 57, 1741-1751.
2. Choi JS, Burm JP: Enhanced nimodipine bioavailability after oral administration of nimodipine with morin, a flavonoid, in rabbits. Arch Pharm Res, 2006, 29, 333-338.
3. Crespi CL, Miller VP, Penman BW: Microtiter plate assays for inhibition of human, drug-metabolizing cytochromes P450. Anal Biochem, 1997, 248, 188-190. (Pubitemid 27218241)
4. Cummins CL, Jacobsen W, Benet LZ: Unmasking the dynamic interplay between intestinal P-glycoprotein and CYP3A4. J Pharmacol Exp Ther, 2002, 300, 1036-1045. (Pubitemid 34165010)
5. Di Pietro A, Conseil G, Pérez-Victoria JM, Dayan G, Baubichon-Cortay H, Trompier D, Steinfels E et al.: Modulation by flavonoids of cell multidrug resistance mediated by P-glycoprotein and related ABC transporters. Cell Mol Life Sci, 2002, 59, 307-322. (Pubitemid 34169516)
6. Dixon RA, Steel CL: Flavonoids and isoflavonoids - a gold mine for metabolic engineering. Trend Plant Sci, 1999, 4, 394-400.
7. Epstein M, Loutzenhister RD: Effects of calcium antagonists on renal hemodynamics. Am J Kidney Dis, 1990, 16, 10-14.
8. Gan LL, Moseley MA, Khosla B, Augustijns PF, Bradshaw TP, Hendren RW, Thakker DR: CYP3A-like cytochrome P450-mediated metabolism and polarized efflux of cyclosporin A in Caco-2 cells: interaction between the two biochemical barriers to intestinal transport. Drug Metab Dispos, 1996, 24, 344-349. (Pubitemid 26087088)
9. Gottesman MM, Pastan I: Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem, 1993, 62, 385-427. (Pubitemid 23237876)
10. Ito K, Kusuhara H, Sugiyama Y: Effects of intestinal CYP3A4 and P-glycoprotein on oral drug absorption theoretical approach. Pharm Res, 1999, 16, 225-231. (Pubitemid 29135126)
11. Kaminsky LS, Fasco MJ: Small intestinal cytochromes P450. Crit Rev Toxicol, 1991, 21, 407-422.
12. Kazda S, Garthoff B, Krause HP, Schlossmann K: Cerebrovascular effects of the calcium antagonistic dihydropyridine derivative nimodipine in animal experiments. Arzneimittelforschung, 1982, 32, 331-338. (Pubitemid 12147516)
13. Kitagawa S, Nabekura T, Takahashi T, Nakamura Y, Sakamoto H, Tano H, Hirai M, Tsukahara G: Structure-activity relationships of the inhibitory effects of flavonoids on P-glycoprotein-mediated transport in KB-C2 cells. Biol Pharm Bull, 2005, 28, 2274-2278. (Pubitemid 41757420)
14. Lee H, Wang HW, Su HY, Hao NJ: The structure-activity relationships of flavonoids as inhibitors of cytochrome P-450 enzymes in rat liver microsomes and the mutagenicity of 2-amino-3-methyl-imidazo[4,5-f]quinoline. Mutagenesis, 1994, 9, 101-106. (Pubitemid 24090150)
15. Lee Y, Yeo H, Liu SH, Jiang Z, Savizky RM, Austin DJ, Cheng YC: Increased anti-P-glycoprotein activity of baicalein by alkylation on a ring. J Med Chem, 2004, 47, 5555-5566. (Pubitemid 39382802)
16. Lin CC, Shieh DE: The anti-inflammatory activity of Scutellaria rivularis extracts and its active components, baicalin, baicalein and wogonin. Am J Chinese Med, 1996, 24, 31-36.
17. Liu A, Yang J, Zhao X, Jiao X, ZhaoW, Ma Q, Tang Z, Dai R: Induction of P450 3A1/2 and 2C6 by gemfibrozil in Sprague-Dawley rats. Pharmacol Rep, 2011, 63, 157-164.
18. Manach C, Regerat F, Texier O, Agullo G, Demigne C, Remesy C: Bioavailability, metabolism and physiological impact of 4-oxo-flavonoids. Nutr Res, 1996, 16, 517-544. (Pubitemid 26084096)
19. Maruhn D, Siefert HM, Weber H, Ramsch K, Suwelack D: Pharmacokinetics of nimodipine. communication: absorption, concentration in plasma and excretion after single administration of nimodipine in rat, dog and monkey. Arzneimittelforschung, 1985, 5, 1781-1786. (Pubitemid 16212382)
20. Matsuzaki Y, Kurokawa N, Terai S, Matsumura Y, Kobayashi N, Okita K: Cell death induced by baicalein in human hepatocellular carcinoma cell lines. Jpn J Cancer Res, 1996, 87, 170-177. (Pubitemid 26099492)
21. Nijveldt RJ, van Nood E, van Hoorn DE, Boelens PG, van Norren K, van Leeuwen PA: Flavonoids: a review of probable mechanisms of action and potential applications. Am J Clin Nutr, 2001, 74, 418-425. (Pubitemid 32880250)
22. Qian M, Gallo JM: High-perfomance liquid chromatographic determinination of the calcium channel blocker nimodipine in monkey plasma. J Chromatogr B, 1992, 578, 316-320.
23. Ramsch KD, Ahr G, Tettenborn D, Auer LM: Overview on pharmacokinetics of nimodipine in healthy volunteer and in patients with subarachnoid hemorrhage. Neurochirurgia, 1985, 28, 74-78. (Pubitemid 15050410)
24. Saeki T, Ueda K, Tanigawara Y, Hori R, Komano T: Pglycoprotein-mediated transcellular transport of MDRreversing agents. FEBS Lett, 1993, 324, 99-102. (Pubitemid 23165045)
25. Sagara K, Ito Y, Oshima T, Misaki T, Murayama H, Itokawa H: Simultaneous determination of baicalein, wogonin, oroxylin-A and their glucuronides in Scutellariae radix by ion-pair high-performance liquid chromatography. J Chromatogr A, 1985, 328, 289-297. (Pubitemid 15068248)
26. Scherling D, Buhner K, Krause HP, Karl W, Wunsche C: Biotransformation of nimodipine in rat, dog and monkey. Arzneimittelforschung, 1991, 41, 392-398.
27. Scholz H: Pharmacological aspects of calcium channel blockers. Cardiovasc Drugs Ther. 1997, 10, 869-872.
28. Shin SC, Li C, Choi JS: Effects of baicalein, an antioxidant, on the bioavailability of doxorubin in rats. Pharmazie, 2009, 64, 579-583.
29. Sutherland L, Ebner T, Burchell B: The expression of UDP- glucuronosyltransferases of the UGT1 family in human liver and kidney and in response to drugs. Biochem Pharmacol, 1993, 45, 295-301. (Pubitemid 23042627)
30. Suwelack D, Weber H, Maruhn D: Pharmacokinetics of nimodipine, communication: absorption, concentration in plasma and excretion after single administration of nimodipine in rat, dog and monkey. Arzneimittelforschung, 1985, 35, 1787-1794.
31. Turgeon D, Carrier JS, Lévesque E, Hum DW, Bélanger A: Relative enzymatic activity, protein stability, and tissue distribution of human steroid-metabolizing UGT2B sub-family members. Endocrinology, 2001, 142, 778-787. (Pubitemid 32222427)
32. Takino Y, Miyahara T, Arichi E, Arichi S, Hayashi T, Karikura M: Determination of some flavonoids in Scutellariae radix by high-performance liquid chromatography. Chem Pharm Bull, 1987, 35, 3494-3497. (Pubitemid 17133565)
33. Wacher VH, Silverman JA, Zhang Y, Benet LZ: Role of P-glycoprotein and cytochrome P450 3A in limiting oral absorption of peptides and peptidomimetics. J Pharm Sci, 1998, 87, 1322-1330. (Pubitemid 28514135)
34. Watkins PB: The barrier function of CYP3A4 and Pglycoprotein in the small bowel. Adv Pharm Drug Deliv Rev, 1996, 27, 161-170.
35. Wolozin B, Kellman W, Ruosseau P, Celesia GG, Siegel G: Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Arch Neurol, 2000, 10, 1439-1443.